1. 1) Michot, J.M., et a1.: Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 54: 139-148, 2016.
2. 2) Larkin, J., et al.: Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 373: 23-34, 2015.
3. 3) Postow, M.A., et al.: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 372: 2006-2017, 2015.
4. 4) Horvat, T.Z., et al.: Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 33: 3193-3198, 2015.
5. 5) Weber, J.S., et al.: Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 30: 2691-2697, 2012.